tgLPD-E1A gene therapy - Targeted Genetics

Drug Profile

tgLPD-E1A gene therapy - Targeted Genetics

Alternative Names: LPD-E1A; TgLOC71

Latest Information Update: 14 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targeted Genetics
  • Developer Targeted Genetics Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer metastases

Most Recent Events

  • 20 Nov 2002 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 07 Aug 2002 Suspended - Preclinical for Cancer metastases in USA (IV)
  • 24 May 2001 Targeted Genetics' synthetic gene delivery technologies, such as the tgLPD-E1A gene therapy, are available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top